Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2024 Publisher: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
Securon SR.
| Pharmaceutical Form |
|---|
|
Modified Release Tablets. The tablets are oblong, pale, green, scored and embossed with two Knoll logos (triangles) on one side. |
Verapamil hydrochloride Ph Eur 240 mg.
| Active Ingredient | Description | |
|---|---|---|
| Verapamil |
Verapamil inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cell. The myocardial oxygen demand is lowered directly as a result of the effect on the energy consuming metabolic processes of the myocardial cell and indirectly due to a reduction of the afterload. Due to its effect on coronary vascular smooth muscle, verapamil enhances myocardial blood flow, even in post‐stenotic areas, and relieves coronary spasms. These properties contribute to the anti‐ischaemic and antianginal efficacy of verapamil in all types of coronary artery disease. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Calendar pack consisting of a PVC/PVDC blister in a cardboard outer container.
Pack size: 28 tablets.
Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
PL 46302/0027
14th March 2002
| Drug | Countries | |
|---|---|---|
| SECURON | Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
